BRPI0905681A2 - "análogos da prolina como ligantes para receptores de canabinóide" - Google Patents
"análogos da prolina como ligantes para receptores de canabinóide"Info
- Publication number
- BRPI0905681A2 BRPI0905681A2 BRPI0905681-5A BRPI0905681A BRPI0905681A2 BR PI0905681 A2 BRPI0905681 A2 BR PI0905681A2 BR PI0905681 A BRPI0905681 A BR PI0905681A BR PI0905681 A2 BRPI0905681 A2 BR PI0905681A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor ligands
- cannabinoid receptor
- proline analogs
- proline
- analogs
- Prior art date
Links
- 102000018208 Cannabinoid Receptor Human genes 0.000 title 1
- 108050007331 Cannabinoid receptor Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000001500 prolyl group Chemical class [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1044708P | 2008-01-08 | 2008-01-08 | |
| PCT/IB2009/000023 WO2009087564A1 (en) | 2008-01-08 | 2009-01-08 | Proline analogs as ligands for cannabinoid receptors for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0905681A2 true BRPI0905681A2 (pt) | 2015-07-07 |
Family
ID=40474987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0905681-5A BRPI0905681A2 (pt) | 2008-01-08 | 2009-01-08 | "análogos da prolina como ligantes para receptores de canabinóide" |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8084612B2 (pt) |
| EP (2) | EP2240443B1 (pt) |
| JP (1) | JP5236748B2 (pt) |
| KR (1) | KR101343399B1 (pt) |
| CN (1) | CN101910126B (pt) |
| AU (1) | AU2009203549B2 (pt) |
| BR (1) | BRPI0905681A2 (pt) |
| CA (2) | CA2711508C (pt) |
| IL (2) | IL206355A0 (pt) |
| MX (1) | MX2010007622A (pt) |
| NZ (1) | NZ586094A (pt) |
| WO (1) | WO2009087564A1 (pt) |
| ZA (1) | ZA201004059B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2350548B1 (es) * | 2009-06-25 | 2011-09-29 | Institut Univ. De Ciència I Tecnologia, S.A. | N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica. |
| CN102869656B (zh) | 2010-04-28 | 2014-03-12 | 安斯泰来制药株式会社 | 四氢苯并噻吩化合物 |
| EP2608787B1 (en) * | 2010-08-24 | 2019-11-20 | Idorsia Pharmaceuticals Ltd | Proline sulfonamide derivatives as orexin receptor antagonists |
| KR101941048B1 (ko) * | 2011-10-27 | 2019-01-22 | 아스텔라스세이야쿠 가부시키가이샤 | 아미노 알킬 치환 n-티에닐벤즈아미드 유도체 |
| CA3185209A1 (en) * | 2020-07-10 | 2021-01-27 | Alyssa WINKLER | Gas41 inhibitors and methods of use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| ES2008634A6 (es) | 1988-10-06 | 1989-07-16 | Lilly Sa | Un procedimiento para la produccion de derivados de tiofeno. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| GB9304156D0 (en) * | 1992-03-26 | 1993-04-21 | Zeneca Ltd | Antibiotic compounds |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| ES2247604T3 (es) | 1995-06-12 | 2006-03-01 | G.D. SEARLE & CO. | Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa. |
| GB9525262D0 (en) * | 1995-12-11 | 1996-02-07 | Bayer Ag | Heterocyclylcarbonyl substituted benzofuranyl-ureas |
| AU750175B2 (en) * | 1997-11-24 | 2002-07-11 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
| EP1558252B1 (en) * | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| US6852748B1 (en) * | 2002-10-30 | 2005-02-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide |
| EP1735286B1 (en) * | 2004-03-24 | 2012-01-04 | Janssen Pharmaceutica NV | Tetrahydro-indazole cannabinoid modulators |
| SE0401342D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| JP4760139B2 (ja) * | 2004-05-28 | 2011-08-31 | 田辺三菱製薬株式会社 | ピロリジン誘導体およびその製法 |
| TW200602314A (en) * | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| CN1960970A (zh) * | 2004-05-28 | 2007-05-09 | 田边制药株式会社 | 作为cb1受体的拮抗剂的吡咯烷衍生物 |
| FR2880890B1 (fr) * | 2005-01-19 | 2007-03-30 | Sanofi Aventis Sa | Derives de n-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide, leur preparation et leur application en therapeutique |
| JP2007262022A (ja) * | 2006-03-29 | 2007-10-11 | Mochida Pharmaceut Co Ltd | 新規２−チオフェンカルボキサミド誘導体 |
-
2009
- 2009-01-08 AU AU2009203549A patent/AU2009203549B2/en not_active Ceased
- 2009-01-08 EP EP09701185.2A patent/EP2240443B1/en active Active
- 2009-01-08 JP JP2010541858A patent/JP5236748B2/ja active Active
- 2009-01-08 CA CA2711508A patent/CA2711508C/en active Active
- 2009-01-08 MX MX2010007622A patent/MX2010007622A/es active IP Right Grant
- 2009-01-08 CN CN200980101878.1A patent/CN101910126B/zh not_active Expired - Fee Related
- 2009-01-08 NZ NZ586094A patent/NZ586094A/en not_active IP Right Cessation
- 2009-01-08 WO PCT/IB2009/000023 patent/WO2009087564A1/en not_active Ceased
- 2009-01-08 EP EP12198206.0A patent/EP2583963A1/en not_active Withdrawn
- 2009-01-08 KR KR1020107017700A patent/KR101343399B1/ko not_active Expired - Fee Related
- 2009-01-08 BR BRPI0905681-5A patent/BRPI0905681A2/pt not_active Application Discontinuation
- 2009-01-08 CA CA2794054A patent/CA2794054C/en active Active
- 2009-01-08 US US12/350,450 patent/US8084612B2/en active Active
-
2010
- 2010-06-08 ZA ZA2010/04059A patent/ZA201004059B/en unknown
- 2010-06-14 IL IL206355A patent/IL206355A0/en active IP Right Grant
-
2013
- 2013-06-06 IL IL226799A patent/IL226799A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009203549A1 (en) | 2009-07-16 |
| US20090291947A1 (en) | 2009-11-26 |
| CA2711508A1 (en) | 2009-07-16 |
| IL226799A0 (en) | 2013-07-31 |
| EP2240443A1 (en) | 2010-10-20 |
| CN101910126B (zh) | 2014-04-30 |
| MX2010007622A (es) | 2011-01-21 |
| IL206355A0 (en) | 2010-12-30 |
| EP2583963A1 (en) | 2013-04-24 |
| CA2794054A1 (en) | 2009-07-16 |
| KR20100113556A (ko) | 2010-10-21 |
| ZA201004059B (en) | 2011-05-25 |
| JP5236748B2 (ja) | 2013-07-17 |
| EP2240443B1 (en) | 2013-11-20 |
| NZ586094A (en) | 2012-06-29 |
| WO2009087564A1 (en) | 2009-07-16 |
| CN101910126A (zh) | 2010-12-08 |
| US8084612B2 (en) | 2011-12-27 |
| CA2711508C (en) | 2013-07-16 |
| JP2011509285A (ja) | 2011-03-24 |
| KR101343399B1 (ko) | 2013-12-19 |
| AU2009203549B2 (en) | 2013-03-07 |
| CA2794054C (en) | 2014-11-25 |
| HK1146270A1 (en) | 2011-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2587805T3 (da) | Tilstandsensartethedssignalering til intra-kodning | |
| BRPI0817562A2 (pt) | derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis | |
| EP2362779A4 (en) | CXCR4 RECEPTOR COMPOUNDS | |
| BRPI0910229A2 (pt) | Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos | |
| EP2262891A4 (en) | EXTRACELLULAR MATRIX COMPOSITIONS | |
| EP2180018A4 (en) | POLYAMIDE COMPOSITION | |
| BRPI0815246A2 (pt) | Composição de catalisador | |
| BRPI0919135A2 (pt) | compostos inéditos como ligantes do receptor canabinóide. | |
| EP2381760A4 (en) | CORN PROTEIN COMPOSITION | |
| EP2320907A4 (en) | THERAPEUTIC COMPOUNDS | |
| BRPI0913806A2 (pt) | "composição" | |
| EP2519525A4 (en) | SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS | |
| EP2491025A4 (en) | AZAAZULENVERBINDUNGEN | |
| BRPI1008939A2 (pt) | 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3. | |
| BR112012008159A2 (pt) | moduladores de receptor canabinoide | |
| DK2326651T3 (da) | Buprenorphinanaloger | |
| EP2268285A4 (en) | THERAPEUTIC COMPOUNDS | |
| BRPI1008899A2 (pt) | derivados 3,3´-espiroindolinona como agentes anticâncer | |
| BRPI0919898A2 (pt) | 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3 | |
| BRPI0918064A2 (pt) | distribuidor de substância | |
| FR2921069B1 (fr) | Composition polyamide | |
| BRPI0814806A2 (pt) | Pirazinas substituídas como antagonistas de cb1 | |
| CU23870B1 (es) | Derivados de ciclopropilamida como moduladores h3 | |
| BRPI0909854A2 (pt) | "arranjo de fracionamento" | |
| BRPI0914063A2 (pt) | composição de xampu concentrado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. PAGAR RESTAURACAO. |
|
| B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2343 DE 01/12/2015. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |